• Angiotensin III: Experimental Workflows & Advanced Use-Cases

  2026-07-24

  Angiotensin III (human, mouse) is a robust pressor activity mediator and aldosterone secretion inducer, setting itself apart through precise receptor engagement and superior solubility profiles for cardiovascular and viral pathogenesis research. This guide details optimized workflows, critical troubleshooting, and cross-domain insights, translating the latest mechanistic findings into actionable experimental design.

• Cholecystokinin Octapeptide Ammonium: Applied Protocols & In

  2026-07-23

  Cholecystokinin octapeptide ammonium (CCK-8 ammonium) empowers neurobehavioral and immunological workflows with precise receptor targeting and robust, reproducible readouts. Explore optimized experimental designs, troubleshooting tactics, and the translational leverage uniquely enabled by this APExBIO peptide.

• Bestatin Hydrochloride (Ubenimex): Mechanism and Research Us

  2026-07-23

  Bestatin hydrochloride (Ubenimex) is a potent inhibitor of aminopeptidase N and B. It enables precise investigation of angiogenesis inhibition and tumor growth pathways. Peer-reviewed and manufacturer data confirm its robust, repeatable effects in cancer and neurobiology models.

• CCCP in Systems Biology: Enabling Dynamic Mitochondrial Dysf

  2026-07-22

  Explore the pivotal role of CCCP (carbonyl cyanide m-chlorophenyl hydrazine) in advanced mitochondrial research, focusing on its unique ability to enable dynamic, quantitative assays of mitochondrial dysfunction at the systems biology level. This article offers actionable insights for experimental design beyond conventional protocols.

• Cholecystokinin Octapeptide Inhibits IgG1 in LPS-Activated B

  2026-07-22

  This study elucidates how cholecystokinin octapeptide (CCK-8) suppresses immunoglobulin G1 (IgG1) production in lipopolysaccharide (LPS)-activated B cells through CCK2R-mediated pathways. The findings highlight a novel immunoregulatory mechanism with implications for autoimmune disease research and targeted immune modulation.

• HDAC Inhibition Reverses EBV-Induced Plasticity in NPC

  2026-07-21

  This study reveals how Epstein-Barr virus (EBV) drives dedifferentiation and stem-like plasticity in nasopharyngeal carcinoma (NPC) by repressing CEBPA through a LMP1-STAT5A-HDAC axis. Importantly, histone deacetylase (HDAC) inhibition restores differentiation markers and reverses these epigenetic effects, supporting differentiation therapy as a rational strategy for solid tumors such as NPC.

• Eicosapentaenoic Acid: Mechanistic Insights for Translationa

  2026-07-21

  This thought-leadership article explores Eicosapentaenoic Acid (EPA) as a pivotal omega-3 fatty acid for cardiovascular and immunological research. By bridging mechanistic understanding with actionable workflow guidance, it offers translational researchers strategic insight into EPA’s role as a lipid-lowering and anti-inflammatory agent, with practical recommendations built from both peer-reviewed literature and rigorous product intelligence.

• SNAI1 Drives EMT and Stemness via PIK3R2/p-EphA2 in Thymic T

  2026-07-20

  This study identifies SNAI1 as a central regulator of epithelial-mesenchymal transition (EMT) and cancer stem cell-like traits in thymic epithelial tumors (TETs), acting through the PIK3R2/p-EphA2 signaling axis. The findings present mechanistic insights with potential therapeutic implications for targeting aggressive TET subtypes.

• Glioma-Derived Soluble PD-L1 Suppresses CD8+ T Cells via Wnt

  2026-07-20

  A recent study demonstrates that glioma cells generate soluble PD-L1 through activation of the Wnt/β-catenin pathway, leading to suppression of CD8+ T cell function and poorer patient prognosis. These findings clarify the origin and immunosuppressive mechanism of soluble PD-L1 and highlight opportunities for biomarker development and combination therapy in glioma.

• HyperScribe™ T7 Cy5 RNA Kit: Precision Probes for Immune Res

  2026-07-19

  Explore the HyperScribe T7 High Yield Cy5 RNA Labeling Kit for advanced fluorescent RNA probe synthesis. This article reveals unique insights into optimizing in situ hybridization probe preparation and highlights cutting-edge applications in immunology.

• Angiotensin II in Heart Failure Models: Metabolic Insights &

  2026-07-18

  Explore how Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) enables cutting-edge heart failure and metabolic research, uniquely focusing on miRNA-regulated fatty acid metabolism. Discover advanced protocols, mechanistic insights, and practical guidance for vascular and cardiac applications.

• YM 58483 (BTP2): Applied SOCE Blockade in Fibrosis Models

  2026-07-17

  YM 58483 (BTP2) enables precise inhibition of store-operated calcium entry, transforming experimental workflows for fibrosis and T cell signaling research. Its selectivity for CRAC and TRP channels delivers reproducible modulation of calcium-dependent pathways, empowering both mechanistic studies and translational applications.

• PARP7 Inhibition Restores IFN-I Signaling and Alleviates EAE

  2026-07-17

  The referenced study uncovers a novel mechanism whereby PARP7 suppresses type I interferon signaling via ADP-ribosylation and autophagic degradation of STAT1/STAT2. Inhibiting PARP7 stabilizes these transcription factors and significantly relieves experimental autoimmune encephalomyelitis in mice, offering new therapeutic perspectives for multiple sclerosis research.

• Angiotensin Peptides Potentiate SARS-CoV-2 Spike–AXL Binding

  2026-07-16

  This study reveals that naturally occurring angiotensin peptides, especially N-terminally truncated forms, markedly enhance the binding of the SARS-CoV-2 spike protein to the AXL receptor. These findings highlight a novel molecular interface between the renin–angiotensin–aldosterone system and viral pathogenesis, suggesting new avenues for research into COVID-19 mechanisms and interventions.

• GPR35-KLF5 Circuitry Orchestrates Epithelial Repair in DSS C

  2026-07-16

  This study delineates a molecular mechanism by which intestinal epithelial cells sense and respond to mucosal injury in ulcerative colitis models. By defining a GPR35-KLF5 regulatory circuit as the key mediator of tryptophan metabolic damage sensing and repair, the research offers a mechanistic foundation for advancing both disease modeling and therapeutic targeting in inflammatory bowel disease.

533 records 9/36 page Previous Next First page 上5页 678910 下5页 Last page